Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) saw a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 10,340,000 shares, a drop of 21.7% from the July 31st total of 13,200,000 shares. Based on an average daily trading volume, of 26,080,000 shares, the short-interest ratio is presently 0.4 days.
Allena Pharmaceuticals Price Performance
NASDAQ:ALNA remained flat at $0.10 during trading hours on Friday. The company's stock had a trading volume of 3,366,902 shares, compared to its average volume of 14,194,126. The company's 50 day moving average is $0.14 and its 200 day moving average is $0.21. Allena Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $1.17.
Get Allena Pharmaceuticals alerts:Institutional Inflows and Outflows
An institutional investor recently bought a new position in Allena Pharmaceuticals stock. Millennium Management LLC bought a new position in shares of Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 173,798 shares of the company's stock, valued at approximately $33,000. Millennium Management LLC owned about 0.16% of Allena Pharmaceuticals as of its most recent SEC filing. 22.52% of the stock is owned by institutional investors and hedge funds.
Allena Pharmaceuticals Company Profile
(Get Rating)Allena Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.
See Also
- Get a free copy of the StockNews.com research report on Allena Pharmaceuticals (ALNA)
- Why This Dip in Advanced Auto Parts May be an Opportunity
- MarketBeat: Week in Review 8/22 – 8/26
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.